Gitnux/Report 2026

Diagnostic Industry Statistics

The global in vitro diagnostics market is estimated at $112.5 billion in 2026, explore diagnostic growth figures, leading companies and operating constraints across AI, automation and regulation.
29Statistics
29Sources
6Sections
1Visuals
17mRead
Diagnostic Industry Statistics
How this report is researched
01Editorial Scope

An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.

02Source Research

AI search agents locate sources and extract each figure together with the document it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 32 days

01 Industry overview

The diagnostic industry at a glance

The global in vitro diagnostics market is estimated at $112.5 billion in 2026, with growth driven by molecular testing, decentralized care, precision medicine and AI-enabled diagnostics.

$112.5B[6]
Global IVD market, 2026
5.4%[6]
IVD CAGR, 2026–2033
47.3%[6]
North America share, 2025
343,000[11]
U.S. clinical lab jobs, 2025
Market size
The global in vitro diagnostics market was valued at $107.4 billion in 2025 and is estimated at $112.5 billion in 2026. The estimates cover diagnostic reagents, instruments, software and services used across clinical laboratories, hospitals and other care settings.[6]
Forecast & CAGR
The market is projected to reach $163.0 billion by 2033, representing a 5.4% compound annual growth rate from 2026 to 2033. Growth is linked to earlier disease detection, molecular and immunodiagnostic adoption, decentralized testing and biomarker-based precision medicine.[6]
Market share & regions
North America held the largest regional share at 47.3% of global IVD revenue in 2025. Asia-Pacific was identified as the fastest-growing region for 2026–2033, while the United States was the largest country market in 2025.[6]
Segmentation
Reagents, kits and consumables represented the largest product category, with 65.8% of the market in 2025. Immunodiagnostics led technologies at 25.6%, infectious diseases led applications at 16.1%, and clinical laboratories led end users at 41.1%.[6]
Key players & concentration
Large multinational participants include Roche, Abbott, Danaher, Siemens Healthineers, Thermo Fisher Scientific, bioMérieux, Becton Dickinson, Quest Diagnostics and Labcorp. Quest Diagnostics reported $11.035 billion in total revenue and $10.785 billion in diagnostic-information-services revenue for 2025; these company figures indicate substantial scale but do not establish a global market-concentration ratio.[9]
Pricing
Quest Diagnostics reported a 0.1% increase in revenue per requisition in 2025, while requisition volume increased 12.3%. The company identifies fee-schedule changes, test mix, payer mix and business mix as factors affecting realized diagnostic pricing.[9]
Trends, drivers & challenges
Key growth drivers include population aging, chronic and infectious disease burden, early detection, molecular testing, decentralized testing and precision medicine. Automation can reduce labor demand, while the U.S. Bureau of Labor Statistics projects clinical laboratory technologist and technician employment to grow 3% from 2025 to 2035, reflecting both demand and productivity pressures.[6][11]
Consumer behavior & competition
Demand is shifting toward faster, more convenient and decentralized testing, including point-of-care and home-based tests, while clinical laboratories remain the largest end-user segment at 41.1% of global IVD revenue in 2025. Competition combines multinational instrument-and-reagent platforms with laboratory service networks and specialized molecular, oncology and genetic-testing providers.[6]
Regulation
The FDA’s 2024 laboratory-developed-test rule phases out its general enforcement-discretion approach, bringing laboratory-manufactured IVDs generally under the same enforcement framework as other IVDs. The phaseout schedule includes registration, listing and labeling requirements beginning May 6, 2026; high-risk premarket review beginning November 6, 2027; and moderate- and low-risk premarket review beginning May 6, 2028, where required.[14]
Latest news
As of September 2026, the FDA reported that it had authorized more than 1,600 AI-enabled medical devices for marketing in the United States. The agency states that these devices can support disease detection and diagnosis and are reviewed through risk-based premarket pathways such as 510(k), De Novo or premarket approval.[14]

02 Ranking

Top 10 Companies in the Diagnostic Industry

The leading companies in the diagnostic industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 21, 2026 · Next review December 21, 2026

Verdict

Roche stands out for diagnostic test scale because it manufactures and delivers approximately 31 billion healthcare tests annually, while Siemens Healthineers focuses on imaging and diagnostics since it runs globally across imaging, diagnostics, cancer care and minimally invasive therapies.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in IVD tests delivery

    Roche

    CH

    Ranked #1 · 9.1 · IVD tests delivery

    Why we picked it: It scales in vitro diagnostics and molecular and pathology testing, supported by revenue growth of 7% and R&D at 19.8% of revenue.

  2. Leader in imaging & diagnostics

    Siemens Healthineers

    DE

    Ranked #2 · 9.0 · Imaging & diagnostics

    Why we picked it: It operates across imaging, laboratory and molecular diagnostics, with 5.9% revenue growth and an operating margin of 16.5%.

  3. Leader in instruments & systems

    Fujifilm Holdings

    JP

    Ranked #4 · 8.9 · Instruments & systems

    Why we picked it: It offers medical imaging and in vitro diagnostic systems, supported by an operating margin of 10.4%.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the diagnostic industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Roche

IVD tests delivery · CH

9.1
2

Siemens Healthineers

Imaging & diagnostics · DE

9.0
3

Labcorp

IVD tests delivery · US

8.9
4

Fujifilm Holdings

Instruments & systems · JP

8.9
5

Thermo Fisher Scientific

Specialty diagnostics · US

8.9
6

GE HealthCare

Diagnostic imaging and pharmaceutical diagnostics · US

8.6
7

Illumina

Genomic and next-generation sequencing diagnostics · US

8.5
8

Danaher

Clinical diagnostics, pathology and life-science diagnostics · US

8.2
9

Hologic

Women's-health and molecular diagnostics · US

8.2
10

BD

Specimen management and diagnostic solutions · US

8.1

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 21, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 21). Top 10 companies in the diagnostic industry. In Diagnostic Industry Statistics. Gitnux. https://gitnux.org/diagnostic-industry-statistics/#top-companies

report visual · Projection

Revenue of medical and diagnostic laboratories, all establishments (United States)

Revenue of medical and diagnostic laboratories, all establishments grew from $67.3B in 2020 to $81.7B in 2024.

$67.3B
Start
+4.96%
CAGR · 4y
$81.7B
Projected
20202024
source-verifiedalfred.stlouisfed.org2024

04 Statistics

Technology & AI

Technology & AI coverage quantifies adoption in lab operations: 17.4% of U.S. medical laboratories reported using artificial intelligence in 2024 ASCP surveys.

AI and automation in the diagnostic industry

  • 4% of 127 surveyed medical-laboratory professionals reported adopting AI or machine-learning tools as an advanced analytics initiative.[1]
  • 69.8% of U.S. laboratories using AI reported providing staff training on AI applications in the 2024 ASCP survey.[2]
  • 17.4% of U.S. medical laboratories reported using artificial intelligence in their laboratory operations in the 2024 ASCP Vacancy Survey.[3]
  • 75.4% of respondents supported implementing AI tools in laboratory work, while 52.2% expected implementation in the near future, in a 2025 laboratory survey.[4]

05 Statistics

Market Intelligence

Market Intelligence ties U.S. revenue and the regulatory test-network scale, including 285,940 non-exempt laboratories registered under CLIA in September 2026.

Market size and service revenue in the diagnostic industry

  • $81.74 billion was U.S. revenue in 2024 for NAICS 62151 medical and diagnostic laboratories, covering analytic services, body-fluid analysis and diagnostic imaging; Census AIES definition.[5]
  • $26.30 billion was U.S. diagnostic-imaging-center revenue in 2024, covering establishments producing patient images on referral from healthcare practitioners.[5]
  • $115.5 billion was the global clinical-diagnostics market in 2024, defined by Grand View Research across instruments and reagents, applications and end-use settings including diagnostic laboratories.[6]
  • $55.44 billion was U.S. medical-laboratory revenue in 2024, excluding diagnostic-imaging-center revenue; Census AIES definition.[5]

Growth forecasts for the diagnostic industry

  • 5.2% is Frost & Sullivan’s projected global clinical-diagnostics CAGR for 2024–2030, reaching approximately $143.31 billion in 2030; scope covers clinical diagnostics market segments and laboratory testing.[7]
  • $143.31 billion is Frost & Sullivan’s projected global clinical-diagnostics market value for 2030, from approximately $105.92 billion in 2024, at a 5.2% CAGR.[7]
  • 6.6% is Grand View Research’s projected global clinical-diagnostics CAGR for 2025–2030, reaching $169.2 billion in 2030; scope includes instruments, reagents, applications and end-use settings.[6]
  • $169.2 billion is the projected global clinical-diagnostics market value for 2030, from $115.5 billion in 2024, at a 6.6% CAGR; study scope includes diagnostic laboratories and home-care settings.[6]

Firm counts and size structure in the diagnostic industry

  • 285,940 non-exempt laboratories were registered under U.S. CLIA in September 2026, including 233,448 waiver laboratories, 21,736 provider-performed-microscopy laboratories, 15,214 compliance laboratories and 15,542 accredited laboratories.[8]
  • 23,603 employer establishments operated in U.S. medical and diagnostic laboratories in 2023 under NAICS 6215, which includes medical laboratories and diagnostic-imaging centers.[5]
  • 301,284 laboratories were registered under U.S. CLIA in September 2026, including exempt and non-exempt laboratories; this broader regulatory population includes testing sites beyond NAICS 6215 employer establishments.[8]

06 Statistics

Delivery & Operations

Delivery & Operations highlights testing access footprint, including approximately 2,400 Quest patient service centers formed in 2024 and 16,635 U.S. medical lab employer establishments in 2024.

Delivery capacity and installed base in the diagnostic industry

  • 16,635 employer establishments operated as U.S. medical laboratories in 2024, representing diagnostic laboratory delivery sites rather than firms alone.[5]
  • 398 imaging centers were in operation at December 31, 2024, across RadNet’s U.S. diagnostic-imaging network, including consolidated and joint-venture centers.[9]
  • Approximately 2,400 patient service centers formed Quest Diagnostics’ U.S. specimen-collection access network in 2024.[10]

07 Statistics

People & Workforce

People & Workforce frames labor demand with May 2024 staffing counts, including 71,050 clinical laboratory technologists and technicians and 45,720 phlebotomists.

Employment and hiring in the diagnostic industry

  • 45,720 phlebotomists worked in U.S. medical and diagnostic laboratories in May 2024.[11]
  • 71,050 clinical laboratory technologists and technicians worked in U.S. medical and diagnostic laboratories in May 2024.[11]
  • 9,540 diagnostic medical sonographers worked in U.S. medical and diagnostic laboratories in May 2024.[11]
  • 17,430 radiologic technologists and technicians worked in U.S. medical and diagnostic laboratories in May 2024.[11]

08 Statistics

Pricing

Pricing shows insurer- and charge-benchmark dispersion, including a median negotiated hemoglobin A1c price of $8.48 across 39 providers in the 2026 analysis.

Fees and price levels in the diagnostic industry

  • The median negotiated price for hemoglobin A1c testing was $8.48 across 39 providers in a 2026 analysis of U.S. insurer-released office-setting prices.[12]
  • Full posted charges for a complete blood count ranged from $27 to $160 in Boston and Connecticut metropolitan hospitals and two national laboratories, while discounted self-pay charges ranged from $8 to $105; data were collected January–April 2024.[13]
  • Full posted charges for ferritin ranged from $58 to $328, while discounted self-pay charges ranged from $17 to $161; data were collected January–April 2024.[13]

09 Statistics

Risk & Compliance

Risk & Compliance anchors enforcement reality with CLIA counts and fee levels, including 301,284 U.S. labs registered under CLIA in September 2026.

Regulation and licensing in the diagnostic industry

  • 15,542 non-exempt U.S. laboratories held CLIA Certificates of Accreditation in September 2026, including 4,257 physician office laboratories.[8]
  • 301,284 U.S. laboratories were registered under CLIA in September 2026, including 116,814 physician office laboratories.[8]
  • The CLIA biennial certificate fee effective January 27, 2024 was $248 for waived laboratories and ranged from $223 to $11,801 for non-waived laboratories by annual test volume.[8]
  • 233,448 non-exempt U.S. laboratories held CLIA Certificates of Waiver in September 2026, including 84,829 physician office laboratories.[8]

Key questions about the diagnostic industry

What is the current size of the in vitro diagnostics market?
The global in vitro diagnostics market is estimated at $112.5 billion in 2026. It was valued at $107.4 billion in 2025.
How fast is the in vitro diagnostics market expected to grow?
The IVD CAGR from 2026 to 2033 is 5.4%. The market is projected to reach $163.0 billion by 2033.
Which companies lead the diagnostic industry?
Roche stands out for diagnostic test scale because it manufactures and delivers approximately 31 billion healthcare tests annually, while Siemens Healthineers focuses on imaging and diagnostics since it runs globally across imaging, diagnostics, cancer care and minimally invasive therapies.
What technology shift is most visible in diagnostics work?
AI-enabled diagnostics scale rapidly in the U.S., with the FDA reporting more than 1,600 authorized AI-enabled medical devices for marketing as of September 2026. In parallel, 17.4% of U.S. medical laboratories reported using artificial intelligence in laboratory operations in the 2024 ASCP Vacancy Survey.
How is the diagnostic market structured between products and services?
Reagents, kits and consumables represented 65.8% of the market in 2025, while 41.1% of global IVD revenue came from clinical laboratories as end users in 2025. The estimates cover diagnostic reagents, instruments, software and services used across care settings.
What compliance timelines affect laboratory-developed tests in 2026?
Beginning May 6, 2026, the FDA’s 2024 laboratory-developed-test rule phases out general enforcement discretion and starts registration, listing, and labeling requirements for laboratory-manufactured IVDs. High-risk premarket review begins November 6, 2027, and moderate- and low-risk review begins May 6, 2028, where required.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 21). Diagnostic Industry Statistics. Gitnux. https://gitnux.org/diagnostic-industry-statistics
MLA
Samuel Norberg. "Diagnostic Industry Statistics." Gitnux, 21 Nov 2026, https://gitnux.org/diagnostic-industry-statistics.
Chicago
Samuel Norberg. 2026. "Diagnostic Industry Statistics." Gitnux. https://gitnux.org/diagnostic-industry-statistics.